- Fresenius Medical Care reported a 1Q operating income of EU246 million, marking a 5.7% decrease year over year.
- The revenue stood at EU4.73 billion, a slight increase of +0.4% from the previous year, meeting the estimated revenue of EU4.72 billion.
- Considering Net income, it turned out to be EU71 million, which is significantly less than the earlier estimation of EU121 million.
- The Basic Earnings per Share (EPS) was reported to be EU0.24, lower than the estimated EU0.43.
- The Company restated its fiscal 2024 outlook, expecting revenue growth in the low- to mid-single-digit percent range from the previous year.
- It also predicts the operating income to grow by a mid- to high-teens percent rate compared to the preceding year.
- Fresenius Medical Care reaffirmed its target of achieving an operating income margin of 10% to 14% by 2025, not considering the effects of portfolio changes.
- The company reported a slightly more favorable operating income than planned at the beginning of the year, according to CEO Helen Giza.
- The initial stages of transformation are proceeding swiftly, generating an additional FME25 savings of €52 million.
A look at Fresenius Medical Care & Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investment analysts believe that Fresenius Medical Care, a company offering kidney dialysis services and related products globally, has a positive long-term outlook based on its Smartkarma Smart Scores. With a solid score of 4 in both Value and Dividend factors, the company demonstrates strong financial health and commitment to rewarding shareholders. Additionally, scoring a 3 in Growth and Resilience factors indicates a steady trajectory and ability to withstand economic challenges. Moreover, with a Momentum score of 4, Fresenius Medical Care shows promising upward momentum in its operations.
Fresenius Medical Care AG & Co. KGaA is well-positioned in the market, offering a wide range of medical services and products for dialysis patients worldwide. The company’s high scores in Value and Dividend factors reflect its financial stability and shareholder-friendly policies. While scoring slightly lower in Growth and Resilience, Fresenius Medical Care’s strong Momentum score suggests continued positive performance in the future. Overall, based on the Smartkarma Smart Scores, the company’s outlook remains positive, indicating a favorable investment opportunity for those looking for long-term growth potential.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
